FDA Awaits GAO Report To Guide Behind-The-Counter Policy
This article was originally published in The Tan Sheet
Executive Summary
The Government Accountability Office's anticipated updated report on a behind-the-counter class of drugs will help shape FDA's policy, according to Connie T. Jung, senior policy advisor for Pharmacy Affairs
You may also be interested in...
Behind The Counter Debate Raises Questions Of Pharmacist Role In Diagnosis
A behind-the-counter class of drugs would inevitably put pharmacists in the position of diagnosing patients' conditions, opponents say
BTC Proponents Cite Pharmacists’ Role; Opponents Question Need
There is one thing agreed on by opponents and proponents of assigning drugs to behind-the-counter status, including representatives from the pharmaceutical industry, drug retailers, the pharmacy and medical professions, researchers and consumer advocates: FDA will need a long time to reach a decision on the issue, they say
FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders